Enlicitide Decanoate and Semaglutide Pharmacokinetic Interactions Explored in Healthy Adults

Managing complex metabolic conditions like hypercholesterolemia and type 2 diabetes often requires polypharmacy. Enlicitide decanoate (MK-0616) is a novel orally active macrocyclic peptide designed to lower LDL-C by inhibiting PCSK9, a key regulator of LDL receptor degradation. Concurrently, semaglutide, a GLP-1 receptor agonist, is a cornerstone therapy for type 2 diabetes and obesity, improving glycemic control and promoting weight loss. Given the potential for patients to benefit from both therapies, understanding any pharmacokinetic (PK) interactions between these two distinct mechanisms is critical to ensure safety and efficacy when co-administered.

This clinical study (MK-0616-023) is designed to investigate the pharmacokinetics of enlicitide decanoate and semaglutide in healthy adult participants. The study aims to determine how the body processes each drug when administered alone, and crucially, when they are taken concurrently. Researchers will measure the concentrations of both enlicitide decanoate and semaglutide in the blood over time, providing insights into their absorption, distribution, metabolism, and excretion profiles under different administration scenarios. This comparative approach will identify any potential drug-drug interactions that could alter systemic exposure.